Loading…
Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low
HER2-low could be found in some patients with triple-negative breast cancer (TNBC). However, its potential impacts on clinical features and tumor biological characteristics in TNBC remain unclear. We enrolled 251 consecutive TNBC patients retrospectively, including 157 HER2-low (HER2 ) and 94 HER2-n...
Saved in:
| Published in: | Breast cancer research : BCR 2023-03, Vol.25 (1), p.34-34, Article 34 |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c564t-54df5f17b131ab0c4c551ab5e6ddf8dc3a9f80914d45646d25371458942fdd583 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c564t-54df5f17b131ab0c4c551ab5e6ddf8dc3a9f80914d45646d25371458942fdd583 |
| container_end_page | 34 |
| container_issue | 1 |
| container_start_page | 34 |
| container_title | Breast cancer research : BCR |
| container_volume | 25 |
| creator | Hu, Xi E Yang, Ping Chen, Songhao Wei, Gang Yuan, Lijuan Yang, Zhenyu Gong, Li He, Li Yang, Lin Peng, Shujia Dong, Yanming He, Xianli Bao, Guoqiang |
| description | HER2-low could be found in some patients with triple-negative breast cancer (TNBC). However, its potential impacts on clinical features and tumor biological characteristics in TNBC remain unclear.
We enrolled 251 consecutive TNBC patients retrospectively, including 157 HER2-low (HER2
) and 94 HER2-negtive (HER2
) patients to investigate the clinical and prognostic features. Then, we performed single-cell RNA sequencing (scRNA-seq) with another seven TNBC samples (HER2
vs. HER2
, 4 vs. 3) prospectively to further explore the differences of tumor biological properties between the two TNBC phenotypes. The underlying molecular distinctions were also explored and then verified in the additional TNBC samples.
Compared with HER2
TNBC, HER2
TNBC patients exhibited malignant clinical features with larger tumor size (P = 0.04), more lymph nodes involvement (P = 0.02), higher histological grade of lesions (P |
| doi_str_mv | 10.1186/s13058-023-01639-y |
| format | article |
| fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_c7dbba3af0e5450595056e25009e3370</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A743733891</galeid><doaj_id>oai_doaj_org_article_c7dbba3af0e5450595056e25009e3370</doaj_id><sourcerecordid>A743733891</sourcerecordid><originalsourceid>FETCH-LOGICAL-c564t-54df5f17b131ab0c4c551ab5e6ddf8dc3a9f80914d45646d25371458942fdd583</originalsourceid><addsrcrecordid>eNptUl1rFDEUHUSxtfoHfJCAL75MzedM8iRlqbZQEETBt5BJ7kyzZJM1mW3Zf292t9auSEhyc3POubnhNM1bgs8Jkd3HQhgWssWUtZh0TLXbZ80p4Z1oBac_nz-JT5pXpSwxJr0U8mVzwjqlJCb8tMmL4KO3JiATHRp8CmnaH29hhpwmiOBnDwX5iObs1wHaCJOZ_R2gIYMpM7ImWsgowx2YUJBBMcUdKPjJDwFQTnVJI7q6_EbbkO5fNy_GCoQ3D_tZ8-Pz5ffFVXvz9cv14uKmtaLjc323G8VI-oEwYgZsuRWiBgI650bpLDNqlFgR7njFd44K1hMupOJ0dE5IdtZcH3RdMku9zn5l8lYn4_U-kfKkTZ69DaBt74bBMDNiEFxgoersgAqMFTDW46r16aC13gwrcBbinE04Ej2-if5WT-lOE4w7IllfFT48KOT0awNl1itfLIRgIqRN0bRXTMke012x9_9Al2mTY_0rTSVmmBJO-F_UZGoHPo6pFrY7UX3R81qRSUUq6vw_qDocrLxNEUZf80cEeiDYnErJMD42SbDe2U4fbKer7fTednpbSe-efs8j5Y_P2G-6ldJb</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2803021414</pqid></control><display><type>article</type><title>Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Hu, Xi E ; Yang, Ping ; Chen, Songhao ; Wei, Gang ; Yuan, Lijuan ; Yang, Zhenyu ; Gong, Li ; He, Li ; Yang, Lin ; Peng, Shujia ; Dong, Yanming ; He, Xianli ; Bao, Guoqiang</creator><creatorcontrib>Hu, Xi E ; Yang, Ping ; Chen, Songhao ; Wei, Gang ; Yuan, Lijuan ; Yang, Zhenyu ; Gong, Li ; He, Li ; Yang, Lin ; Peng, Shujia ; Dong, Yanming ; He, Xianli ; Bao, Guoqiang</creatorcontrib><description>HER2-low could be found in some patients with triple-negative breast cancer (TNBC). However, its potential impacts on clinical features and tumor biological characteristics in TNBC remain unclear.
We enrolled 251 consecutive TNBC patients retrospectively, including 157 HER2-low (HER2
) and 94 HER2-negtive (HER2
) patients to investigate the clinical and prognostic features. Then, we performed single-cell RNA sequencing (scRNA-seq) with another seven TNBC samples (HER2
vs. HER2
, 4 vs. 3) prospectively to further explore the differences of tumor biological properties between the two TNBC phenotypes. The underlying molecular distinctions were also explored and then verified in the additional TNBC samples.
Compared with HER2
TNBC, HER2
TNBC patients exhibited malignant clinical features with larger tumor size (P = 0.04), more lymph nodes involvement (P = 0.02), higher histological grade of lesions (P < 0.001), higher Ki67 status (P < 0.01), and a worse prognosis (P < 0.001; HR [CI 95%] = 3.44 [2.10-5.62]). Cox proportional hazards analysis showed that neoadjuvant systemic therapy, lymph nodes involvement and Ki67 levels were prognostic factors in HER2
TNBC but not in HER2
TNBC patients. ScRNA-seq revealed that HER2
TNBC which showed more metabolically active and aggressive hallmarks, while HER2
TNBC exhibited signatures more involved in immune activities with higher expressions of immunoglobulin-related genes (IGHG1, IGHG4, IGKC, IGLC2); this was further confirmed by immunofluorescence in clinical TNBC samples. Furthermore, HER2
and HER2
TNBC exhibited distinct tumor evolutionary characteristics. Moreover, HER2
TNBC revealed a potentially more active immune microenvironment than HER2
TNBC, as evidenced by positively active regulation of macrophage polarization, abundant CD8
effector T cells, enriched diversity of T-cell receptors and higher levels of immunotherapy-targeted markers, which contributed to achieve immunotherapeutic response.
This study suggests that HER2
TNBC patients harbor more malignant clinical behavior and aggressive tumor biological properties than the HER2
phenotype. The heterogeneity of HER2 may be a non-negligible factor in the clinical management of TNBC patients. Our data provide new insights into the development of a more refined classification and tailored therapeutic strategies for TNBC patients.</description><identifier>ISSN: 1465-542X</identifier><identifier>ISSN: 1465-5411</identifier><identifier>EISSN: 1465-542X</identifier><identifier>DOI: 10.1186/s13058-023-01639-y</identifier><identifier>PMID: 36998014</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Bar codes ; Breast cancer ; Breast Neoplasms ; Cancer therapies ; CD8 antigen ; Clinical outcomes ; Effector cells ; ErbB-2 protein ; Female ; Gene expression ; HER2-low ; Heterogeneity ; Humans ; Immunofluorescence ; Immunotherapy ; Ki-67 Antigen ; Lymph nodes ; Lymphocytes T ; Macrophages ; Medical prognosis ; Medical records ; Medical research ; Medicine, Experimental ; Microenvironments ; Phenotypes ; Prognosis ; Retrospective Studies ; RNA sequencing ; Single-cell RNA sequencing ; T cells ; Triple Negative Breast Neoplasms - drug therapy ; Triple Negative Breast Neoplasms - therapy ; Triple-negative breast cancer ; Tumor microenvironment ; Tumor Microenvironment - genetics ; Tumors</subject><ispartof>Breast cancer research : BCR, 2023-03, Vol.25 (1), p.34-34, Article 34</ispartof><rights>2023. The Author(s).</rights><rights>COPYRIGHT 2023 BioMed Central Ltd.</rights><rights>2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c564t-54df5f17b131ab0c4c551ab5e6ddf8dc3a9f80914d45646d25371458942fdd583</citedby><cites>FETCH-LOGICAL-c564t-54df5f17b131ab0c4c551ab5e6ddf8dc3a9f80914d45646d25371458942fdd583</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061837/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2803021414?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36998014$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hu, Xi E</creatorcontrib><creatorcontrib>Yang, Ping</creatorcontrib><creatorcontrib>Chen, Songhao</creatorcontrib><creatorcontrib>Wei, Gang</creatorcontrib><creatorcontrib>Yuan, Lijuan</creatorcontrib><creatorcontrib>Yang, Zhenyu</creatorcontrib><creatorcontrib>Gong, Li</creatorcontrib><creatorcontrib>He, Li</creatorcontrib><creatorcontrib>Yang, Lin</creatorcontrib><creatorcontrib>Peng, Shujia</creatorcontrib><creatorcontrib>Dong, Yanming</creatorcontrib><creatorcontrib>He, Xianli</creatorcontrib><creatorcontrib>Bao, Guoqiang</creatorcontrib><title>Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low</title><title>Breast cancer research : BCR</title><addtitle>Breast Cancer Res</addtitle><description>HER2-low could be found in some patients with triple-negative breast cancer (TNBC). However, its potential impacts on clinical features and tumor biological characteristics in TNBC remain unclear.
We enrolled 251 consecutive TNBC patients retrospectively, including 157 HER2-low (HER2
) and 94 HER2-negtive (HER2
) patients to investigate the clinical and prognostic features. Then, we performed single-cell RNA sequencing (scRNA-seq) with another seven TNBC samples (HER2
vs. HER2
, 4 vs. 3) prospectively to further explore the differences of tumor biological properties between the two TNBC phenotypes. The underlying molecular distinctions were also explored and then verified in the additional TNBC samples.
Compared with HER2
TNBC, HER2
TNBC patients exhibited malignant clinical features with larger tumor size (P = 0.04), more lymph nodes involvement (P = 0.02), higher histological grade of lesions (P < 0.001), higher Ki67 status (P < 0.01), and a worse prognosis (P < 0.001; HR [CI 95%] = 3.44 [2.10-5.62]). Cox proportional hazards analysis showed that neoadjuvant systemic therapy, lymph nodes involvement and Ki67 levels were prognostic factors in HER2
TNBC but not in HER2
TNBC patients. ScRNA-seq revealed that HER2
TNBC which showed more metabolically active and aggressive hallmarks, while HER2
TNBC exhibited signatures more involved in immune activities with higher expressions of immunoglobulin-related genes (IGHG1, IGHG4, IGKC, IGLC2); this was further confirmed by immunofluorescence in clinical TNBC samples. Furthermore, HER2
and HER2
TNBC exhibited distinct tumor evolutionary characteristics. Moreover, HER2
TNBC revealed a potentially more active immune microenvironment than HER2
TNBC, as evidenced by positively active regulation of macrophage polarization, abundant CD8
effector T cells, enriched diversity of T-cell receptors and higher levels of immunotherapy-targeted markers, which contributed to achieve immunotherapeutic response.
This study suggests that HER2
TNBC patients harbor more malignant clinical behavior and aggressive tumor biological properties than the HER2
phenotype. The heterogeneity of HER2 may be a non-negligible factor in the clinical management of TNBC patients. Our data provide new insights into the development of a more refined classification and tailored therapeutic strategies for TNBC patients.</description><subject>Bar codes</subject><subject>Breast cancer</subject><subject>Breast Neoplasms</subject><subject>Cancer therapies</subject><subject>CD8 antigen</subject><subject>Clinical outcomes</subject><subject>Effector cells</subject><subject>ErbB-2 protein</subject><subject>Female</subject><subject>Gene expression</subject><subject>HER2-low</subject><subject>Heterogeneity</subject><subject>Humans</subject><subject>Immunofluorescence</subject><subject>Immunotherapy</subject><subject>Ki-67 Antigen</subject><subject>Lymph nodes</subject><subject>Lymphocytes T</subject><subject>Macrophages</subject><subject>Medical prognosis</subject><subject>Medical records</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Microenvironments</subject><subject>Phenotypes</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>RNA sequencing</subject><subject>Single-cell RNA sequencing</subject><subject>T cells</subject><subject>Triple Negative Breast Neoplasms - drug therapy</subject><subject>Triple Negative Breast Neoplasms - therapy</subject><subject>Triple-negative breast cancer</subject><subject>Tumor microenvironment</subject><subject>Tumor Microenvironment - genetics</subject><subject>Tumors</subject><issn>1465-542X</issn><issn>1465-5411</issn><issn>1465-542X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptUl1rFDEUHUSxtfoHfJCAL75MzedM8iRlqbZQEETBt5BJ7kyzZJM1mW3Zf292t9auSEhyc3POubnhNM1bgs8Jkd3HQhgWssWUtZh0TLXbZ80p4Z1oBac_nz-JT5pXpSwxJr0U8mVzwjqlJCb8tMmL4KO3JiATHRp8CmnaH29hhpwmiOBnDwX5iObs1wHaCJOZ_R2gIYMpM7ImWsgowx2YUJBBMcUdKPjJDwFQTnVJI7q6_EbbkO5fNy_GCoQ3D_tZ8-Pz5ffFVXvz9cv14uKmtaLjc323G8VI-oEwYgZsuRWiBgI650bpLDNqlFgR7njFd44K1hMupOJ0dE5IdtZcH3RdMku9zn5l8lYn4_U-kfKkTZ69DaBt74bBMDNiEFxgoersgAqMFTDW46r16aC13gwrcBbinE04Ej2-if5WT-lOE4w7IllfFT48KOT0awNl1itfLIRgIqRN0bRXTMke012x9_9Al2mTY_0rTSVmmBJO-F_UZGoHPo6pFrY7UX3R81qRSUUq6vw_qDocrLxNEUZf80cEeiDYnErJMD42SbDe2U4fbKer7fTednpbSe-efs8j5Y_P2G-6ldJb</recordid><startdate>20230330</startdate><enddate>20230330</enddate><creator>Hu, Xi E</creator><creator>Yang, Ping</creator><creator>Chen, Songhao</creator><creator>Wei, Gang</creator><creator>Yuan, Lijuan</creator><creator>Yang, Zhenyu</creator><creator>Gong, Li</creator><creator>He, Li</creator><creator>Yang, Lin</creator><creator>Peng, Shujia</creator><creator>Dong, Yanming</creator><creator>He, Xianli</creator><creator>Bao, Guoqiang</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20230330</creationdate><title>Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low</title><author>Hu, Xi E ; Yang, Ping ; Chen, Songhao ; Wei, Gang ; Yuan, Lijuan ; Yang, Zhenyu ; Gong, Li ; He, Li ; Yang, Lin ; Peng, Shujia ; Dong, Yanming ; He, Xianli ; Bao, Guoqiang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c564t-54df5f17b131ab0c4c551ab5e6ddf8dc3a9f80914d45646d25371458942fdd583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Bar codes</topic><topic>Breast cancer</topic><topic>Breast Neoplasms</topic><topic>Cancer therapies</topic><topic>CD8 antigen</topic><topic>Clinical outcomes</topic><topic>Effector cells</topic><topic>ErbB-2 protein</topic><topic>Female</topic><topic>Gene expression</topic><topic>HER2-low</topic><topic>Heterogeneity</topic><topic>Humans</topic><topic>Immunofluorescence</topic><topic>Immunotherapy</topic><topic>Ki-67 Antigen</topic><topic>Lymph nodes</topic><topic>Lymphocytes T</topic><topic>Macrophages</topic><topic>Medical prognosis</topic><topic>Medical records</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Microenvironments</topic><topic>Phenotypes</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>RNA sequencing</topic><topic>Single-cell RNA sequencing</topic><topic>T cells</topic><topic>Triple Negative Breast Neoplasms - drug therapy</topic><topic>Triple Negative Breast Neoplasms - therapy</topic><topic>Triple-negative breast cancer</topic><topic>Tumor microenvironment</topic><topic>Tumor Microenvironment - genetics</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hu, Xi E</creatorcontrib><creatorcontrib>Yang, Ping</creatorcontrib><creatorcontrib>Chen, Songhao</creatorcontrib><creatorcontrib>Wei, Gang</creatorcontrib><creatorcontrib>Yuan, Lijuan</creatorcontrib><creatorcontrib>Yang, Zhenyu</creatorcontrib><creatorcontrib>Gong, Li</creatorcontrib><creatorcontrib>He, Li</creatorcontrib><creatorcontrib>Yang, Lin</creatorcontrib><creatorcontrib>Peng, Shujia</creatorcontrib><creatorcontrib>Dong, Yanming</creatorcontrib><creatorcontrib>He, Xianli</creatorcontrib><creatorcontrib>Bao, Guoqiang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Breast cancer research : BCR</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hu, Xi E</au><au>Yang, Ping</au><au>Chen, Songhao</au><au>Wei, Gang</au><au>Yuan, Lijuan</au><au>Yang, Zhenyu</au><au>Gong, Li</au><au>He, Li</au><au>Yang, Lin</au><au>Peng, Shujia</au><au>Dong, Yanming</au><au>He, Xianli</au><au>Bao, Guoqiang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low</atitle><jtitle>Breast cancer research : BCR</jtitle><addtitle>Breast Cancer Res</addtitle><date>2023-03-30</date><risdate>2023</risdate><volume>25</volume><issue>1</issue><spage>34</spage><epage>34</epage><pages>34-34</pages><artnum>34</artnum><issn>1465-542X</issn><issn>1465-5411</issn><eissn>1465-542X</eissn><abstract>HER2-low could be found in some patients with triple-negative breast cancer (TNBC). However, its potential impacts on clinical features and tumor biological characteristics in TNBC remain unclear.
We enrolled 251 consecutive TNBC patients retrospectively, including 157 HER2-low (HER2
) and 94 HER2-negtive (HER2
) patients to investigate the clinical and prognostic features. Then, we performed single-cell RNA sequencing (scRNA-seq) with another seven TNBC samples (HER2
vs. HER2
, 4 vs. 3) prospectively to further explore the differences of tumor biological properties between the two TNBC phenotypes. The underlying molecular distinctions were also explored and then verified in the additional TNBC samples.
Compared with HER2
TNBC, HER2
TNBC patients exhibited malignant clinical features with larger tumor size (P = 0.04), more lymph nodes involvement (P = 0.02), higher histological grade of lesions (P < 0.001), higher Ki67 status (P < 0.01), and a worse prognosis (P < 0.001; HR [CI 95%] = 3.44 [2.10-5.62]). Cox proportional hazards analysis showed that neoadjuvant systemic therapy, lymph nodes involvement and Ki67 levels were prognostic factors in HER2
TNBC but not in HER2
TNBC patients. ScRNA-seq revealed that HER2
TNBC which showed more metabolically active and aggressive hallmarks, while HER2
TNBC exhibited signatures more involved in immune activities with higher expressions of immunoglobulin-related genes (IGHG1, IGHG4, IGKC, IGLC2); this was further confirmed by immunofluorescence in clinical TNBC samples. Furthermore, HER2
and HER2
TNBC exhibited distinct tumor evolutionary characteristics. Moreover, HER2
TNBC revealed a potentially more active immune microenvironment than HER2
TNBC, as evidenced by positively active regulation of macrophage polarization, abundant CD8
effector T cells, enriched diversity of T-cell receptors and higher levels of immunotherapy-targeted markers, which contributed to achieve immunotherapeutic response.
This study suggests that HER2
TNBC patients harbor more malignant clinical behavior and aggressive tumor biological properties than the HER2
phenotype. The heterogeneity of HER2 may be a non-negligible factor in the clinical management of TNBC patients. Our data provide new insights into the development of a more refined classification and tailored therapeutic strategies for TNBC patients.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>36998014</pmid><doi>10.1186/s13058-023-01639-y</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1465-542X |
| ispartof | Breast cancer research : BCR, 2023-03, Vol.25 (1), p.34-34, Article 34 |
| issn | 1465-542X 1465-5411 1465-542X |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_c7dbba3af0e5450595056e25009e3370 |
| source | Publicly Available Content Database; PubMed Central |
| subjects | Bar codes Breast cancer Breast Neoplasms Cancer therapies CD8 antigen Clinical outcomes Effector cells ErbB-2 protein Female Gene expression HER2-low Heterogeneity Humans Immunofluorescence Immunotherapy Ki-67 Antigen Lymph nodes Lymphocytes T Macrophages Medical prognosis Medical records Medical research Medicine, Experimental Microenvironments Phenotypes Prognosis Retrospective Studies RNA sequencing Single-cell RNA sequencing T cells Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - therapy Triple-negative breast cancer Tumor microenvironment Tumor Microenvironment - genetics Tumors |
| title | Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T14%3A56%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20and%20biological%20heterogeneities%20in%20triple-negative%20breast%20cancer%20reveals%20a%20non-negligible%20role%20of%20HER2-low&rft.jtitle=Breast%20cancer%20research%20:%20BCR&rft.au=Hu,%20Xi%20E&rft.date=2023-03-30&rft.volume=25&rft.issue=1&rft.spage=34&rft.epage=34&rft.pages=34-34&rft.artnum=34&rft.issn=1465-542X&rft.eissn=1465-542X&rft_id=info:doi/10.1186/s13058-023-01639-y&rft_dat=%3Cgale_doaj_%3EA743733891%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c564t-54df5f17b131ab0c4c551ab5e6ddf8dc3a9f80914d45646d25371458942fdd583%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2803021414&rft_id=info:pmid/36998014&rft_galeid=A743733891&rfr_iscdi=true |